Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Allarity Therapeutics, Inc. (ALLR)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Visitors trend2W10W9M
0.4400+0.0309 (+7.55%)
At close: 12:59PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Short-term KST

Short-term KST

Performance Outlook
Previous Close0.4091
Open0.4800
Bid0.4500 x 800
Ask0.4400 x 800
Day's Range0.4100 - 0.4800
52 Week Range0.3610 - 18.2000
Volume52,378
Avg. Volume107,849
Market Cap4.514M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.8660
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ALLR

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Allarity Therapeutics, Inc.
    Daily – Vickers Top Insider Picks for 11/23/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • GlobeNewswire

    Allarity Therapeutics Reports Third Quarter 2022 Financial Results

    Press release Cambridge, MA U.S.A. (November 15, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care today reported financial results for the third quarter ended September 30, 2022. Balance Sheet: As of September 30, 2022, Allarity’s cash was $3.9 million, as compared to $19.6 million as of December 31, 2021. R&D Expense

  • GlobeNewswire

    Allarity Therapeutics Announces Adjournment of 2022 Annual Meeting of Stockholders

    Press release Cambridge, MA U.S.A. (November 7, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care today announced that the Company’s 2022 Annual Meeting of Stockholders (the “Meeting”), was convened on November 4, 2022, at 1:00 p.m. (Eastern Time) and was adjourned without any business being conducted. The Meeting was

  • News Direct

    Precision Medicine Could Get Even More Precise With Allarity Therapeutics’ “Next-Generation” Diagnostics Platform

    By Rachael Green, Benzinga

Advertisement
Advertisement